Abbott, Edwards Lifesciences Corporation and LivaNova PLC are Dominating the Global Heart Valve Repair and Replacement Market in 2021

 

Global Heart Valve Repair and Replacement Market is expected to grow with the CAGR of 10.6% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-heart-valve-repair-and-replacement-market

Global heart valve repair and replacement market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in global heart valve repair and replacement market are introducing strong range of products provider along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In December 2020, Abbott launched a minimally-invasive heart valve repair device in India to treat mitral regurgitation. It will help restore the heart’s ability to pump oxygenated blood more efficiently and help improve the company’s revenue.

Abbott is the dominating player in global heart valve repair and replacement market. The other key players existing in the market includes Medtronic, LivaNova PLC, NeoChord, Inc., Meril Life Sciences Pvt. Ltd., Micro Interventional Devices, Inc., MVRx, Inc., MeKo Laser Material Processing, Foldax, Inc., Comed B.V., Neovasc Inc., Colibri Heart Valve, HLT, CardiaMed, XELTIS, JenaValve Technology, Inc., Edwards Lifescinces Corporation, and BIOTRONIK SE & Co. KG among others.

Heart Valve Repair and Replacement MarketAbbott

Abbott was founded in 1888 and is headquartered in Illinois, U.S. The company focuses on manufacturing of devices in order to manage chronic pain and diabetes among others. The company has following business segments established pharmaceutical products, nutritionals, diagnostics, medical devices, other and out of which, the market focused segment is medical devices. The company is providing products under cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicines. The market focus products lie under cardiovascular product category.   

For instance,

  • In December 2020, Abbott launched a minimally-invasive heart valve repair device in India to treat mitral regurgitation. It will help restore the heart’s ability to pump oxygenated blood more efficiently and help improve the company’s revenue.

The company has wide presence Americas, Europe, Middle East and Africa, and Asia-Pacific. The company also has various subsidiary companies such as Abbott Cardiovascular Systems Inc. (U.S.), Abbott Nutrition Manufacturing Inc. (U.S.), Abbott Laboratories Pacific Ltd. (U.S.), Abbott Resources Inc. (U.S.) and PDD II, LLC (U.S.) among others.

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation was founded in 1958 and is headquartered in California, U.S. The company is the global leader in patient-focused medical innovations for structural heart disease as well as critical care and monitoring. The business segment includes trans catheter aortic valve replacement, trans catheter mitral and tricuspid therapies, surgical heart valve therapy, and critical care. The focused business segments are trans catheter aortic valve replacement, trans catheter mitral and tricuspid therapies, and surgical heart valve therapy.  The company is providing products under trans catheter heart valves, surgical valves repair, surgical valve replacement, bovine pericardial patches, hemodynamic monitoring, decision support software, pressure monitoring, vascular catheters, accessories and instruments, and support. The market focus products lie under trans catheter heart valves, surgical valves repair, and surgical valve replacement. The company has initiated many strategic initiatives to expand its market.

For instance,

  • In May, Edwards Lifesciences Corporation announced that it has received CE mark approval from the European regulatory body for its Edwards Pascal trans catheter valve repair system to treat patients with tricuspid regurgitation. This will help the company in the expansion of its business in Europe.

The company has wide presence across Americas, Europe, Asia-Pacific, and Middle East and Africa. The company also has various subsidiary companies such as CAS Medical Systems, Inc. (California), Valtech Cardio Ltd. (Israel), Edwards Lifesciences Pty Ltd. (Australia), Edwards Lifesciences (India) Private Ltd. (India), and Edwards Lifesciences Mexico S.A (Mexico) among others.

LivaNova PLC

LivaNova PLC was incorporated in 1987, and is headquartered in London, U.K. The company is a global medical technology company engaged in cardiovascular and neuromodulation solutions. The company has business segments such as cardiopulmonary, heart valves, advanced circulatory support, cardiovascular, and neuromodulation among which heart valves is focused business segment. The company is providing products advanced circulatory support, cardiopulmonary, difficult-to-treat depression, and drug-resistance epilepsy. Heart failure, heart valves, obstructive sleep apnea and heart valves are the market focused categories.

  • In July 2020, LivaNova PLC announced its new product Perceval plus aortic heart valve in Europe. It will facilitate minimally invasive cardiac surgery and help the company to expand its business further.

The company has wide presence across Americas, Europe, Middle East and Africa, and Asia-Pacific. The company has various subsidiary companies such as Corcym S.r.l. (Italy), Sorin Group Italia S.r.l. (Italy), CardiacAssist Inc. (U.S.), LivaNova Switzerland SA (Switzerland), and Sorin Group USA Inc. (U.S.) among others. The company has initiated many strategic initiatives to expand its market.